Research Article

You have full text access to this OnlineOpen article

Efficacy of infliximab in resistant psoriatic arthritis

  1. Carlo Salvarani1,*,
  2. Fabrizio Cantini2,
  3. Ignazio Olivieri3,
  4. Pierluigi Macchioni1,
  5. Angela Padula3,
  6. Laura Niccoli2,
  7. Maria Grazia Catanoso1,
  8. Giovanni Lo Scocco1,
  9. Luigi Boiardi1

Article first published online: 1 AUG 2003

DOI: 10.1002/art.11201

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 49, Issue 4, pages 541–545, 15 August 2003

Additional Information

How to Cite

Salvarani, C., Cantini, F., Olivieri, I., Macchioni, P., Padula, A., Niccoli, L., Catanoso, M. G., Scocco, G. L. and Boiardi, L. (2003), Efficacy of infliximab in resistant psoriatic arthritis. Arthritis & Rheumatism, 49: 541–545. doi: 10.1002/art.11201

Author Information

  1. 1

    Arcispedale S. Maria Nuova, Reggio Emilia, Italy

  2. 2

    Ospedale Civile, Prato, Italy

  3. 3

    Ospedale San Carlo, Potenza, Italy

*Divisione di Reumatologia, Arcispedale S. Maria Nuova, V.le Umberto 1°, 50, 42100 Reggio Emilia, Italy

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 1 AUG 2003
  3. Manuscript Accepted: 5 SEP 2002
  4. Manuscript Received: 7 OCT 2001

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (70K)

REFERENCES

  • 1
    Gladman DD, Schuckett R, Russel ML, Thorne JC, Schacter RK. Psoriatic arthritis (PSA): an analysis of 220 patients. Q J Med 1987; 62: 127–41.
  • 2
    Gladman DD, Stafford-Brady F, Chang CH, Lewandosky K, Russel ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809–12.
  • 3
    Gordon DA, Stein JL, Broder I. The extra-articular features of rheumatoid arthitis: a systematic analysis of 127 cases. Am J Med 1973; 55: 445–52.
  • 4
    Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veteran Affairs cooperative study. Arthritis Rheum 1996; 39: 2013–20.
    Direct Link:
  • 5
    Combe B, Goupille P, Kuntz JL, Tebib J, Liote F, Bregeon C. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 1996; 35: 664–8.
  • 6
    Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984; 27: 376–81.
    Direct Link:
  • 7
    Espinoza LR, Zakraoui L, Espinoza CG, Gutierrez F, Jara LJ, Silveira LH, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992; 19: 872–7.
  • 8
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346–52.
    Direct Link:
  • 9
    Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428–33.
  • 10
    Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000; 18: 732–4.
  • 11
    Mease PJ, Goffe BS, Metz J, Van der Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–90.
  • 12
    Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755–65.
    Direct Link:
  • 13
    Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821–2.
  • 14
    Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349–56.
  • 15
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002; 359: 1187–93.
  • 16
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial: ATTRACT study group. Lancet 1999; 354: 1932–9.
  • 17
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy study group. N Engl J Med 2000; 343: 1594–602.
  • 18
    Calin A, Porta J, Fries JF, Schurman J. Clinical history as a screening for ankylosing spondylitis. JAMA 1977; 237: 2613–4.
  • 19
    Dougados M, Gueguen A, Nakache JP, Nguyen M, Amor B. Evaluation of a functional index for patients with ankylosis spondylitis. J Rheumatol 1990; 17: 1254–5.
  • 20
    MacRae IF, Wright V. Measurement of back movement. Ann Rheum Dis 1969; 28: 584–9.
  • 21
    Fredericksson T, Petterson U. Severe psoriasis oral therapy with a new retinoid. Dermatologica 1978; 157: 238–44.
  • 22
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. The American College of Rheumatology preliminary definitions of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 1–9.
    Direct Link:
  • 23
    Food and Drug Administration. Guidance for industry: clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA). February 1999. Accessed April 18, 2003. URL: www.fda.gov/cber/guidelines.htm.
  • 24
    Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518–23.
  • 25
    Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000; 43: 1244–56.
    Direct Link:
  • 26
    Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: 618–27.
    Direct Link:
  • 27
    Brockbank JE, Lapp V, Gladman DD. Infliximab therapy in 15 patients with psoriatic arthritis (PsA). J Rheumatol 2001; 28 Suppl 63: 62.
View Full Article (HTML) Get PDF (70K)